



UNITED STATES PATENT AND TRADEMARK OFFICE

100
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/526,151	02/28/2005	Claire Ashman	PG4939A	7463
20462	7590	03/08/2007	EXAMINER	
SMITHKLINE BEECHAM CORPORATION			HORNING, MICHELLE S	
CORPORATE INTELLECTUAL PROPERTY-US, UW2220			ART UNIT	PAPER NUMBER
P. O. BOX 1539			1648	
KING OF PRUSSIA, PA 19406-0939				

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	03/08/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No.	Applicant(s)	
	10/526,151	ASHMAN ET AL.	
Examiner	Art Unit		
Michelle Horning	1648		

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 28 February 2005.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-8 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) Claim(s) _____ is/are allowed.
6) Claim(s) 1-8 is/are rejected.
7) Claim(s) _____ is/are objected to.
8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____
4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____
5) Notice of Informal Patent Application
6) Other: _____

DETAILED ACTION

This office action is responsive to communication filed 2/28/2005. The status of the claims is as follows: claims 1-8 are under current examination.

IDS

The information disclosure statement filed 2/28/2005 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered.

Objection to the Specification

The disclosure is objected to because of the following informalities: the specification fails to describe the all of the drawings. There are a total of 18 individual figures. The specification only describes Figures 1-3 on page 18 and Figures 6-14 on page 17. The specification does not contain a brief description of the drawings section.

Appropriate correction is required.

Claim Rejections

35 U.S.C. 112, 1st paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the

art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-8 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Enablement is considered in view of the *Wands* factor (MPEP 2164.01(aa)).

Nature of the invention. The claims are drawn to a vaccine composition for the treatment of asthma or COPD comprising an immunogen that generates an immune response to self IL-13 and an adjuvant comprising a CpG-containing immunostimulatory oligonucleotide and a saponin.

State of the prior art. It is well known in the prior art that blockade of IL-13 reverses allergen-induced increases in mucus-containing cell in airways via neutralization of IL-13. Further, this cytokine is known to play a role in both asthma and COPD.

Breadth of the claims. The claims are broad, encompassing any and all vaccine compositions comprising any and all immunogens against self IL-13 and any and all CpG-containing immunostimulatory oligonucleotides. Further, the immunogen may induce any and all types of immune responses.

Working examples. The working examples do *not* demonstrate the claimed invention. Instead, they are drawn to both *in vitro* and *in vivo* IL-13 neutralization in mice. Of note, in the *in vivo* example, mice were treated with rabbit anti-mouse IL-13

polyclonal antibody during an ovalbumin challenge and certain parameters were quantified. There are no working examples that demonstrate "an immunogen that generates an immune response in a vaccine against self IL-13". There are no examples drawn to COPD.

Guidance in the specification. The specification provides little to no guidance regarding the claimed composition. While the sequences of many putative immunogens are provided, there are no data supporting that these sequences will generate an immune response in combination with an adjuvant that will ultimately treat either asthma or COPD. The specification is based on theory and fails to provide any evidence that the immunogens will function as claimed.

Predictability of the art. The physiological art in general is acknowledged to be unpredictable (MPEP 2164.03). In the instant application, Applicants have not disclosed the actual gain in the treatment asthma or COPD using the claimed composition. Further, it is noted that "3. Vaccination studies" (page 31-32 of the specification) is in future tense, suggesting the work has not yet been completed and further work in monitoring the level of anti-mouse IL-13 antibodies and IL-13 neutralization capacity is required. There is no way that one of ordinary skill in the art can predict the outcome of the claimed vaccine composition in treating either asthma or COPD.

Amount of experimentation necessary. Applicants have identified a composition based on an interesting theory (entire specification), but essentially all of the work required to develop a valid vaccine composition for the treatment of asthma or COPD as claimed has been left for others.

For the reasons discussed above, it would require undue experimentation for one skilled in the art to make the claimed compositions.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1 and 3 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1 and 2 of copending Application No. US2006/0147417. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a vaccine composition comprising human IL-13 and foreign T-helper epitopes.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

CONCLUSION


No claim is allowed.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michelle Horning whose telephone number is 571-272-9036. The examiner can normally be reached on Monday-Friday, 8:30 am to 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 570-272-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for unpublished application is available through Private PAIR only. For more information about PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at

866-217-9197 (toll-free).


Michelle Horning
Patent Examiner


Bruce Campell

BRUCE R. CAMPELL, PH.D
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600